Results 301 to 310 of about 365,877 (337)
Erratum: Ginseng-Derived Exosomes Attenuate Immune Evasion in NSCLC via PD-L1 Modulation [Corrigendum]. [PDF]
Cancer Manag Reseuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Onkologische Welt, 2023
Nach Daten der Studie FLAURA2 zeigt Osimertinib plus Chemotherapie in der Behandlung des nicht-kleinzelligen Lungenkarzinoms (NSCLC) einen statistisch signifikanten Vorteil beim progressionsfreien Überleben (PFS) im Vergleich zu Osimertinib allein. Studienleiter Dr. Pasi Jänne, Boston (USA), stellte die Ergebnisse der Studie vor.
openaire +1 more source
Nach Daten der Studie FLAURA2 zeigt Osimertinib plus Chemotherapie in der Behandlung des nicht-kleinzelligen Lungenkarzinoms (NSCLC) einen statistisch signifikanten Vorteil beim progressionsfreien Überleben (PFS) im Vergleich zu Osimertinib allein. Studienleiter Dr. Pasi Jänne, Boston (USA), stellte die Ergebnisse der Studie vor.
openaire +1 more source
Onkologische Welt, 2023
Mittlerweile sind synergistische Effekte bei Kombination von Immuntherapie und Angiogenesehemmung in der Behandlung des nicht-kleinzelligen Lungenkarzinoms (NSCLC) bekannt. Das bestätigt die Phase-III-Studie EAST ENERGY, in der das Regime Pembrolizumab/Ramucirumab zu einer hohen Rate pathologischer Remissionen und R0-Resektionen führte.
openaire +1 more source
Mittlerweile sind synergistische Effekte bei Kombination von Immuntherapie und Angiogenesehemmung in der Behandlung des nicht-kleinzelligen Lungenkarzinoms (NSCLC) bekannt. Das bestätigt die Phase-III-Studie EAST ENERGY, in der das Regime Pembrolizumab/Ramucirumab zu einer hohen Rate pathologischer Remissionen und R0-Resektionen führte.
openaire +1 more source
Cemiplimab (Libtayo) for NSCLC
The Medical Letter on Drugs and Therapeutics, 2023The FDA has approved cemiplimab-rwlc (Libtayo – Regeneron), an immune checkpoint inhibitor, for use in combination with platinum-based chemotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults with no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1 aberrations
openaire +2 more sources
Capmatinib (Tabrecta) for NSCLC
The Medical Letter on Drugs and Therapeutics, 2023The FDA has granted regular approval to the oral kinase inhibitor capmatinib (Tabrecta – Novartis) for treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. MET exon 14 skipping mutations occur in 3-4% of NSCLC cases.
openaire +2 more sources
Lung Cancer, 2004
The prognosis of bronchogenic carcinoma in stage III N2 is poor. Five-year survival ranges between 0 and 5%. Lymph-node involvement itself still is the main prognostic factor. Complete lymphadenectomy improves long-term survival in contrast to lymph-node sampling.
Godehard, Friedel +4 more
openaire +2 more sources
The prognosis of bronchogenic carcinoma in stage III N2 is poor. Five-year survival ranges between 0 and 5%. Lymph-node involvement itself still is the main prognostic factor. Complete lymphadenectomy improves long-term survival in contrast to lymph-node sampling.
Godehard, Friedel +4 more
openaire +2 more sources
Sotorasib (Lumakras) for NSCLC
The Medical Letter on Drugs and Therapeutics, 2023Sotorasib (Lumakras — Amgen), an oral KRAS inhibitor, has received accelerated approval by the FDA for treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who received at least one prior systemic therapy.
openaire +2 more sources